Last reviewed · How we verify
Emgality (GALCANEZUMAB)
Emgality works by binding to calcitonin gene-related peptide 1 (CGRP1), preventing it from triggering migraine attacks.
Galcanezumab (Emgality) is a marketed preventive treatment for migraine by Eli Lilly, competing in a class that includes erenumab, fremanezumab, eptinezumab, ubrogepant, and rimegepant. Its key strength lies in its mechanism of action, which involves binding to CGRP1 to prevent migraine attacks, aligning it with other effective CGRP inhibitors. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | GALCANEZUMAB |
|---|---|
| Sponsor | Eli Lilly |
| Target | Calcitonin gene-related peptide 1 |
| Modality | Monoclonal antibody |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2018 |
| Annual revenue | 500 |
Mechanism of action
Galcanezumab-gnlm is humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Approved indications
- Preventive treatment of migraine
- Treatment of episodic cluster headache
Common side effects
- Injection site reactions
- Episodic Cluster Headache
- Anaphylaxis
- Angioedema
- Rash
- Injection site pain
- Injection site erythema
- Injection site pruritus
- Anti-galcanezumab-gnlm antibody development
- Neutralizing antibodies
Key clinical trials
- Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action (PHASE4)
- A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine (PHASE3)
- Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia (PHASE4)
- A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine (PHASE3)
- Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease (EARLY_PHASE1)
- Migraine Medication Effects on Urinary Symptoms
- Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies
- Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |